RGX-104 is an orally bioavailable and potent liver-X nuclear hormone receptor (LXR) agonist that modulates innate immunity via transcriptional activation of the ApoE gene.
IC50&Target
LXR
体内研究
Oral administration of RGX-104 (100 mg/kg, daily) to animals bearing palpable tumors significantly suppresses the growth of multiple cancer types. Co-administration of RGX-104 with anti-PD-1 is superior to administration of either RGX-104 or anti-PD-1 alone. Importantly, co-administration of RGX-104 with anti-PD-1 therapy is well tolerated by mice, with no overt signs of toxicity.
Animal Model:
NOD SCID or RAG mice injected with 1×10 SKOV3 ovarian cancer cells.
Dosage:
100 mg/kg.
Administration:
Oral administration daily for about 60 days.
Result:
Robustly suppressed tumor growth and progression.
分子式
C34H33ClF3NO3
分子量
596.08
CAS号
610318-54-2
运输条件
Room temperature in continental US; may vary elsewhere.